Genective Completes Key Executive Succession as Growth Continues in the U.S.

Genective, a joint venture between Limagrain and KWS, announces the appointment of Thomas Clark, Ph.D., as VP of Research and CSO, succeeding Francois Torney, Ph.D.

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Genective, a joint venture between Limagrain and KWS, announces the appointment of Thomas Clark, Ph.D., as VP of Research and CSO, succeeding Francois Torney, Ph.D. Clark brings over 30 years of experience in agricultural product development, previously holding leadership roles at Provivi and Monsanto. His expertise is expected to strengthen Genective's capabilities in transgenic traits, particularly insect control technologies. The change in leadership is aligned with Genective's aim to enhance its research engine and meet increasing market demands sustainably.

Positive

Appointment of Thomas Clark as VP of Research and CSO is expected to bring valuable experience to Genective.
Clark has over 30 years of experience in agriculture and previous roles at leading companies enhancing Genective's leadership strength.
Continued focus on developing next-generation insect traits aligns with market demands for sustainable agriculture.

Negative

None.

Argus Session date unavailable

+0.44% session move Open Argus

Details

News Market Reaction – BAYRY

The recorded move for BAYRY in the trading session of this news was +0.44%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

03/31/2023 - 09:00 AM EDT

CHAMPAIGN, III., March 31, 2023 /PRNewswire/ -- Genective, a joint venture between Limagrain and KWS dedicated to the research, development, and commercialization of transgenic traits, is pleased to announce Thomas Clark, Ph.D. as VP of Research, CSO. Dr. Clark will succeed current CSO, Francois Torney, Ph.D., who will complete his assignment to Genective later in 2023 and return to Limagrain as planned.

"Francois played a critical leadership role in transforming our research pipeline and positioning Genective well for the next stage of growth in the years to come," said Qiaoni Linda Jing, President & CEO of Genective. "I thank Francois for his dedication and tremendous contribution to Genective and wish him all the best in Limagrain."

"I am excited to welcome Tom to Team Genective," Jing continued. "Tom's deep knowledge in science, coupled with his broad experience spanning research, development and commercialization make him the ideal CSO as Genective continues to grow our business and contribution to the industry."

Tom has over 30 years of product development experience in agriculture and joins Genective from Provivi, Inc. where he was Sr. Vice President of Global Field Development. Prior to that, he spent 13 years focused on the development of biotech insect control traits and global insect management strategy at Monsanto. Tom holds a B.S. in biology from California State University, Stanislaus, an M.S. and Ph.D. in entomology (agronomy) from the University of Nebraska-Lincoln and has more than 60 peer-reviewed publications and patents. He currently resides in Missouri with his family on their livestock farm.

"Genective has built a powerful research engine that is well positioned to bring next generation insect traits that will benefit farmers as they meet ever increasing demands to deliver more yield to the marketplace in a sustainable manner," said Clark. "I am excited to join this talented team of scientists as we bring new insect control technologies that will positively impact how farmers manage problematic to control pests while ensuring long-term growth and opportunity for Genective."

About Genective

Genective is a 50/50 joint venture between Limagrain and KWS, two of the world's largest seed companies. With entities and activities in North America, South America, Europe, and Asia, Genective is dedicated to the research, development, and commercialization of transgenic traits.

Media Contact: Erin Yarling
erin.yarling@genective.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/genective-completes-key-executive-succession-as-growth-continues-in-the-us-301786192.html

SOURCE Genective

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the new VP of Research and CSO at Genective?

Thomas Clark, Ph.D., has been appointed as the new VP of Research and CSO at Genective.

What experience does Thomas Clark bring to Genective?

Thomas Clark brings over 30 years of product development experience in agriculture, previously serving at Provivi and Monsanto.

What is Genective focusing on under Thomas Clark's leadership?

Genective aims to enhance its research in transgenic traits, particularly in developing insect control technologies.

What role did Francois Torney play at Genective?

Francois Torney served as CSO and played a critical role in transforming Genective's research pipeline before his transition back to Limagrain.

When did the executive change take place at Genective?

The announcement of Thomas Clark's appointment was made on March 31, 2023.

Genective Completes Key Executive Succession as Growth Continues in the U.S.